INTRODUCTION
When insulin treatment is started in patients with type 2 diabetes mellitus (T2DM), there are many regimens that control serum glucose levels to a normal range. Basal-bolus insulin therapy is one of the most effective treatments for improving glycemic control to prevent the progression of diabetic microvascular complications [1] . This is because this regimen can stimulate the secretion of insulin from Islets of Langerhans at meal times. However, basal-bolus regimen requires four daily injections [2] . There are other insulin treatments with fewer daily injections which can achieve good glycemic control similar to that achieved with basal-bolus treatment. This is usually preferred by patients with T2DM, as a smaller number of daily injections can maintain their quality of life and compliance [3] . In addition, research by United Kingdom Prospective Diabetes Study (UKPDS) strongly suggests that intensive treatment prevented diabetic microangiopathy complications independent of insulin usage [4] ; it is important to maintain good glycemic control levels regardless of multiple or single insulin injections. Recent studies demonstrated that twice-daily treatments with biphasic insulin aspart 70/30 (BIAsp 30) [5, 6] and premixed insulin lispro-50/50 (Mix50) [3] could have equal effects on glycemic control and convey better quality of life than basal-bolus therapy in insulin-naïve patients. In addition, basal insulin (glargine) plus oral treatment showed effects equivalent to basal-bolus treatment [7] . Although these regimens are not always effective for all patients with (T2DM), a therapy with fewer insulin injections might be favored by physicians and patients.
The first 1-2-3 study was performed in the United States [8] . It demonstrated the efficacy of step-up treatment using premixed insulin BIAsp 30, and the practicality of once-daily injection of BIAsp 30 was shown. In addition, twice-daily injection treatment of BIAsp 30, which is used widely [9] , was shown to have beneficial effects on glycemic control in a study by Valensi et al. [9] . Subsequently, a similar 1-2-3 study performed in Japan demonstrated that BIAsp 30 step-up therapy was a safe, simple therapy that could achieve better glycemic control [10] .
Overall, BIAsp 30 step-up therapy has demonstrated efficacy as a continuing insulin treatment to control glycemic levels regardless of ethnicity.
On the other hand, Mix50 containing 50% lispro and 50% neutral protamine lispro (NPL) is widely used as a twice-daily insulin regimen [11] . The regimen of premixed insulin Mix50 administered three times daily before meals can maintain good glucose control compared with twice-daily injection of humulin 30/70 insulin treatment [12] , or with basal plus oral antidiabetic drug (OAD) treatment in insulinnaïve patients with T2DM [13] . However, the beneficial effects of step-up therapy using Mix50 have not been clarified. Therefore, the present study was conducted to determine whether Japanese patients with type 2 diabetes mellitus could achieve better glycemic control with step-up insulin treatment with premixed insulin Mix50 than with BIAsp 30. 
METHODS

Subjects
Statistical Analysis
All data were analyzed with JMP7 Ò Japanese version analytic software (SAS Japan, Tokyo, Japan 
RESULTS
Seventy-two patients with T2DM were enrolled in this study. Patient baseline characteristics are shown in Table 1 . No significant differences in any parameters at baseline were seen between BIAsp 30 and Mix50 groups (Table 1) . Sixty-four patients completed this study, and eight patients (four in BIAsp 30 and four in Mix50 group) refused to the increasing number of insulin injections required to proceed from step 2 to step 3.
Glycemic Control
The cumulative percentage of subjects who achieved HbA1c \7.4% was 36.1% (13/36) for the target HbA1c \7.4% in the Mix50 group. The HbA1c levels of 9.9 ± 1.7% at the baseline of the study significantly decreased to 7.8 ± 1.0% after 16 weeks (completion of step-1), 7.8 ± 1.0% after 32 weeks (completion of step-2), and 8.2 ± 0.9% after 48 weeks the Mix50n group, HbA1c levels of 9.6 ± 1.6% at the baseline of the study were significantly decreased to 7.8 ± 0.9% after 16 weeks (completion of step-1), 7.6 ± 0.9% after 32 weeks (completion of step-2), and 7.7 ± 0.9% after 48 weeks (completion of step-3). There was no significant difference in HbA1c
or FPG between the two groups at any observation point ( Table 2 ). The HbA1c levels of patients who achieved target HbA1c \7.4% significantly decreased in each step (Table 3) ; however, the HbA1c levels of patients who did not achieve target
HbA1c\7.4% were difficult to reduce regardless of the number of insulin injections and the insulin dosage. In addition, the fasting blood glucose levels of uncontrolled patients did not decrease from step 1 to step 2 in either group.
Insulin Dosage
The daily BIAsp 30 dosages for the patients who achieved target HbA1c \7.4% in step 1 were 0.12 U/kg at the start, 0.18 U/kg at the completion of step 1, and in step 2 were 0.14 U/kg at the start and 0.40 U/kg at the completion of step 2, and in step 3 were 0.11 U/ kg at the start and 0.64 U/kg at the completion of step 3. In addition, the daily BIAsp 30 doses for the uncontrolled patients were 0.11 U/kg at the start and 0.63 U/kg at the completion of HbA1c (%) 0 week 9.9 ± 1.7 (n = 36) 9.6 ± 1.6 (n = 36) 0.353 16 ± 2 week 7.8 ± 1.0* (n = 36) 7.8 ± 0.9* (n = 36) 0.978 32 ± 2 week 7.8 ± 1.2* (n = 32) 7.8 ± 0.9* (n = 32) 0.638 48 ± 2 week 8.2 ± 0.9* (n = 9) 7.7 ± 0.9* (n = 29.2 ± 6.2* 1-Injection: subjects could achieve targeted HbA1c in step 1, 2-Injection: subjects could achieve targeted HbA1c in step 2, and 3-Injection: subjects could achieve targeted HbA1c in step 3. ' 'Uncontrolled' ' means subjects who were not able to achieve target HbA1c\7.4% despite receiving of taking thrice-daily treatment with BIAsp 30 or Mix50 insulin Values are given as mean ±
SD
The were 0.11 U/kg at the start, 0.15 U/kg at the completion of step 1, and in step 2 were 0.10 U/ kg at the start, 0.32 U/kg at the completion of step 2, and in step 3 were 0.12 U/kg at the start, 0.56 U/kg at the completion of the step 3. In addition, the daily Mix50 dosages for the uncontrolled patients were 0.09 U/kg at the start and 0.56 U/kg at the completion of step 3 ( Table 3 ). The insulin doses between the two groups were not significantly different in each step.
Body Mass Index
No significant change was seen in BMI in either group of patients who achieved target HbA1c in (Table 3) .
Moreover, the basal BMI of uncontrolled patients was significantly higher than that of patients who achieved target HbA1c (29. 
DISCUSSION
Graber et al. [8] showed the usefulness of stepup therapy with BIAsp 30 in a 1-2-3 study performed in USA. They indicated that the cumulative rates of patients achieving the target HbA1c B6.5% and 7.0% were 21% and 41% with once-daily injection, 52% and 70%
with twice-daily injection, and 60% and 77%
with thrice-daily injection. Yoshioka et al. [10] demonstrated the usefulness of step-up therapy with BIAsp 30 in Japanese T2DM patients. They showed that the cumulative rates of achievement of HbA1c \6.5% and \7.0% were 5.1% and 21.2% with once-daily injection, Moreover, the present study demonstrated that insulin step-up treatment with Mix50
showed an effect on glycemic control equal to that with BIAsp 30. Although more increasing number should be needed, the ratio of patients achieving target HbA1c in thrice-daily injection of Mix50 (7/13: 53.8%) was better than that with BIAsp 30 (1/9: 11.1%) (P = 0.04).
There are some merits to initiating insulin treatment by step-up regimen using biphasic insulin. One is that step-up treatment is a simple method because only one insulin device is required, and only once-daily injection before dinner is introduced at the start. Therefore, it is easily acceptable for not only physicians, but also patients as a routine clinical treatment. Previous 1-2-3 studies demonstrated the usefulness of once-daily injection of BIAsp 30 [8, 10] . Moreover, a small dose of BIAsp 30 once a day before dinner in combination with OADs was shown to be effective for glycemic control [15, 16] The probable explanation for the effect of oncedaily injection of Mix50 before dinner is that for most Japanese the main meal of the day is dinner, which has a high glycemic index since it includes foods such as rice, as Roach et al. [17] demonstrated that the greater proportion of rapid-acting insulin analog was more effective for carbohydrate-rich meals.
The prevalence of diabetes with obesity is increasing worldwide. In general, it is difficult to achieve target glycemic control in the treatment of obese diabetic patients because of high insulin resistance [18] . When insulin is initiated in these patients, higher insulin dosage is required and must be increased [19] . The results of the present study show that the basal BMI of uncontrolled patients who failed to achieve target HbA1c \7.4% regardless of thrice-daily injection of BIAsp 30 or Mix50 was significantly higher than that of patients who achieved target HbA1c. During the study, the BMI of uncontrolled patients increased significantly in both groups. However, the rate of increase of BMI was similar to that of a previous study [20] . In addition, their fasting blood glucose levels did not decrease with the step 2 treatment, suggesting that their insulin resistance might be high, although plasma c-peptide was not assessed in this study. Lifestyle modifications with diet and exercise are the most essential for the management of obese diabetic patients, and combination of OADs to decrease insulin resistance or of basal insulin, such as glargine to decrease the fasting blood glucose and to minimize weight gain compared with that with rapid or premixed insulin, should be considered when insulin therapy is required for the treatment of obese, diabetic patient [21] .
There were several limitations in the present study. One of the limitations was that the diurnal plasma glucose measurement was not performed in the outpatient setting and, therefore, the effect of insulin treatment on diurnal plasma glucose change was not fully assessed. Second, the target of HbA1c \7.4% was slightly higher than HbA1c \6.5% that the JDS recommends as good glycemic control to prevent microvascular complications [22] . 
